131Iodine-Tenatumomab Treatment In Tenascin-C Positive Cancer Patients

Study Overview

131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

Tenatumomab is a Sigma-Tau developed new anti-Tenascin antibody. It is a murine monoclonal antibody directed towards Tenascin-C. By means of this antibody, Tenascin-C expression was studied on a commercial tissue array slides each carrying malignant breast, colorectal, lung, ovarian or B and T cell Non-Hodgkin Limphoma tissue sections. All these cancers type showed positivity to Tenascin-C between the 64% and 13.3%. Consequently, Sigma-tau is exploring the use of the 131I-labeled Tenatumomab for anti-cancer radioimmunotherapy.

This will be an open-label dose escalation study. The study will be conducted in two steps: 1. STEP A aims to identify the optimal amount of antibody to convey the specific radio-label activity of radionuclide. 2. STEP B will be conducted with the amount of antibody chosen in STEP A, and an escalating radio-labeled therapeutic dose response curve will be performed (3.5 to 5.5 GBq) A maximum of 36 evaluable patients suffering from treatment-refractory Tenascin-C positive tumors. This dose escalation study will be evaluated using descriptive statistics: no sample size calculation was performed Primary objectives 1. To identify the Maximum Tolerated Dose (MTD) and assess Safety and Tolerability of i.v. infused 131I-Tenatumomab. 2. To identify the optimal amount of unlabeled Tenatumomab able to convey 131I- Tenatumomab with the highest Tumor/nonTumor ratio. 3. To evaluate the whole body Dosimetry (safety dosimetry) and Tumor to normal tissue ratio (T/nT ratio, referred to AUC) of i.v.infused 131I-Tenatumomab. 4. To evaluate intra-lesional distribution and retention of 131I-Tenatumomab and to record individual lesion dosimetry. 5. To evaluate systemic biodistribution, pharmacokinetics, urinary excretion and dose linearity of 131I-Tenatumomab. Secondary objectives 1. To evaluate proportional 131I-Tenatumomab tumor binding, as a function of the total load. 2. To evaluate Pharmacokinetics of Tenatumomab (protein and protein related materials) in serum. 3. To evaluate preliminary Efficacy of 131I-Tenatumomab based on disease response rate (Complete Response, Partial Response, Stable Disease) and patient's general clinical condition by ECOG performance status assessment.

Breast Neoplasm
Head and Neck Neoplasm
Skin Neoplasm
Respiratory Tract Neoplasm
Urogenital Neoplasm
Digestive System Neoplasm
Pancreatic Neoplasm
Connective and Soft Tissue Neoplasm
Lymphoma, Non-Hodgkin

COMBINATION_PRODUCT: 131I-Tenatumomab

TENATUMOMAB/ST2146-CR-14-001
2014-003832-38 (EUDRACT_NUMBER Identifier) (EUDRACT_NUMBER: )

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2015-11-09	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2018-09-14
First Submitted that Met QC Criteria 2015-11-09	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2018-09-18
First Posted (ACTUAL) 2015-11-11	Results First Posted N/A	Last Verified 2018-01

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: 131I-Tenatumomab Diagnostic: each patient will receive one single i.v. infusion of 370 MBq±10% 131I-Tenatumomab in 10 ml of saline (conveyed by 10 ±10%, 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333 ° µl	COMBINATION_PRODUCT: 131I-Tenatumomab I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: 131I-Tenatumomab

Diagnostic: each patient will receive one single i.v. infusion of 370 MBq±10% 131I-Tenatumomab in 10 ml of saline (conveyed by 10 ±10%, 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333 ° µl

COMBINATION_PRODUCT: 131I-Tenatumomab

I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C

Primary Outcome Measures	Measure Description	Time Frame
Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03)	no more details necessary	up to six weeks

Secondary Outcome Measures	Measure Description	Time Frame
Adverse Events	no more details necessary	up to 1 year

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

1. Written informed consent.
2. A patient who has (a) a histologically documented advanced tumor that has relapsed from, or is refractory to, standard treatment and for which no other standard treatment is available and (b) confirmed Tenascin-C expression obtained through a biopsy on at least one reachable tumor lesion.

3. Agreement to hemopoietic stem cell collection procedures (the procedure will be performed upon clinical evaluation of the Investigator and if deemed necessary in the interest of the patient).
4. Male or female ≥18 years of age
5. Eastern Cooperative Oncology Group (ECOG), or WHO performance status of ≤ 2 or Karnofsky > 60
6. Life expectancy of at least 3 months.
7. Negative pregnancy test for all women of child-bearing potential. Appropriate contraception (one highly effective method or a combination of acceptable methods) is to be used during the study period and until 90 days after the last follow-up visit (End of Study Visit)
8. Hematological, thyroid, liver, cardiac and renal function test results ≤ grade 2 toxicity (according to US National Cancer Institute's "Common Terminology Criteria for Adverse Events v4.03 [CTCAE]"), e.g.:

Hematocrit ≥ 30%
Hemoglobin ≥ 9.0 g/dl
White blood cell count ≥ 3 x 109/L
Neutrophils > 1.5 x109/L
Platelets ≥ 100x 109/L

Alanine transaminase, Aspartate transaminase, Alkaline Phosphatase ≤ 2.5 times institutional upper limit of normal (ULN) or ≤5 x ULN in presence of liver metastases.
Bilirubin ≤ 1.5 x ULN or ≤3 x ULN in presence of liver metastases.

Urine protein: ≤30 mg/dl or dipstick: ≤3
eGFR≥60 ml/min/1.73 m2 (with Chronic kideny disease-Epidemiology collaboration formula)

1. Known hypersensitivity to Tenatumomab, Iodine or any excipient.
2. Active infection at screening or history of severe infection within the previous 2 months, if considered clinically relevant by the Investigator.
3. Positive test to Human Immunodeficiency Virus (HIV) and/or chronically active Hepatitis B or C.
4. Patients with primary Central nervous system tumor or cerebral metastases.
5. Administration of another investigational medicinal product within 45days before the screening period.
6. Previous treatment with any radiopharmaceutical within a period corresponding to 8 half-lives of the radionuclide used prior to the administration of study drug.
7. History of somatic or psychiatric disease/condition that may interfere with the objectives of the study.
8. Major illness, trauma, or surgery within 2 weeks before the screening period, if considered clinically significant by the Investigator.
9. Patient who underwent chemotherapy and/or radiation therapy and/or treatments with biologics (which are not to be of murine origin) within 4 weeks before the screening period.
10. Women who are breast feeding, due to the potential risk of damage to the infant.
11. Men unwilling to use appropriate contraceptive methods during the study and up to 90 days after the last follow-up visit (End of Study Visit).
12. Bladder catheterization cannot be performed, or the patient is unwilling to be catheterized if necessary.
13. Murine antibodies treated patients. It is at the discretion of the Investigator to exclude patients who have worsened considerably from screening to Day -1.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Medpace, Inc.

Investigators

STUDY_CHAIR: SECONDO LASTORIA, M.D., ISTITUTO NAZIONALE DEI TUMORI IRCCS - FONDAZIONE "G. PASCALE" NAPLES - ITALY

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record